1. Volume 392, Issue 10162, Pages 2353-2366 (December 2018)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial 
Christopher C Parker, MD, Prof Nicholas D James, PhD, Christopher D Brawley, MSc, Prof Noel W Clarke, ChM, Alex P Hoyle, MRCS, Adnan Ali, MBBS, Alastair W S Ritchie, MD, Prof Gerhardt Attard, MD, Simon Chowdhury, PhD, William Cross, PhD, Prof David P Dearnaley, FRCR, Prof Silke Gillessen, MD, Clare Gilson, MRCP, Prof Robert J Jones, PhD, Prof Ruth E Langley, PhD, Zafar I Malik, FRCR, Prof Malcolm D Mason, MD, David Matheson, PhD, Robin Millman, J Martin Russell, MBChB, Prof George N Thalmann, MD, Claire L Amos, PhD, Roberto Alonzi, MD, Amit Bahl, FRCP, Alison Birtle, FRCR, Omar Din, MD, Hassan Douis, PhD, Chinnamani Eswar, FRCR, Joanna Gale, FRCP, Melissa R Gannon, MSc, Sai Jonnada, FRCR, Sara Khaksar, FRCR, Jason F Lester, FRCR, Prof Joe M O'Sullivan, MD, Omi A Parikh, FRCR, Ian D Pedley, MBChB, Delia M Pudney, MBChB, Denise J Sheehan, FRCR, Narayanan Nair Srihari, FRCR, Anna T H Tran, FRCR, Prof Mahesh K B Parmar, DPhil, Matthew R Sydes, MSc 
The Lancet 
Volume 392, Issue 10162, Pages (December 2018)
DOI: /S (18)
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 2 Overall survival and failure-free survival, by treatment
HR=hazard ratio. Solid lines show the Kaplan-Meier analysis and dotted lines show the flexible parametric model.
The Lancet  , DOI: ( /S (18) )
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions